Substituted Pyrrolidine Factor XIa Inhibitors for Thromboembolic Disease Treatment
Solution Overview
Problem
Current treatments for thromboembolic diseases, which target factor XIa, often face challenges in achieving optimal inhibitory selectivity and safety without bleeding side effects.
Innovation Solution
A compound represented by formula (I), specifically a pyrrolidine derivative, is developed to serve as a potent and selective inhibitor of factor XIa, offering improved inhibitory activity and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If factor XIa inhibitors are used to treat thromboembolic diseases, then anti-thrombotic effect is improved, but bleeding side effects occur
Solution Approach 1:
The patent applies local quality by designing a inhibitor compound with specific structural features (formula I) that target factor XIa selectively. The molecular structure includes specific substituents (R1-R6, Cyc A-Cyc E) that are optimized to interact with the factor XIa active site, providing localized inhibition at the target enzyme while sparing other coagulation factors, thus achieving strong anti-thrombotic effect with reduced bleeding risk
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical parameters of the inhibitor compound (different substituents R1-R6, different cyclic groups Cyc A-Cyc E, different linkers) to optimize the balance between inhibitory potency and selectivity. By adjusting these molecular parameters, the compound achieves high affinity for factor XIa while maintaining selectivity against other serine proteases, resolving the contradiction between efficacy and safety
2Reliability
If factor XIa inhibition is enhanced to improve anti-thrombotic effect, then selectivity for factor XIa must be maintained to avoid bleeding
Solution Approach 1:
The patent applies local quality by incorporating specific structural elements in the inhibitor molecule that are tailored to match the unique features of the factor XIa active site. The substituted pyrrolidine core with specific side chain arrangements creates local interactions (hydrogen bonds, hydrophobic contacts) that are characteristic of factor XIa binding, enabling high selectivity even at high inhibition levels
Solution Approach 2:
The patent uses the inhibitor compound as an intermediary that selectively binds to factor XIa. The molecular structure acts as a mediator that translates the specificity requirements into a chemical form that can discriminate between factor XIa and other coagulation factors, achieving both high inhibition and high selectivity simultaneously
Data Source
AI summary
The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.